Core Viewpoint - Huahai Pharmaceutical has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Group 1 - Huahai Pharmaceutical announced the approval of injectable Nicorandil on November 17 [1] - The approval allows the product to be considered as having passed the consistency evaluation under the relevant national policies [1] - This new product approval is expected to enrich the company's product offerings [1]

Group 1 - The core point of the article is that Huahai Pharmaceutical has received approval from the National Medical Products Administration for the injection of Nicorandil, which is a significant development for the company [1] - Huahai Pharmaceutical's revenue composition for the year 2024 is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - As of the report, Huahai Pharmaceutical has a market capitalization of 27.8 billion yuan [1]

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, marking a significant milestone for the company in the cardiovascular drug market [1] Company Summary - The injectable Nicorandil is indicated for unstable angina and was originally developed by Chugai Pharmaceutical Co., Ltd., being launched in Japan in September 1993 [1] - Currently, the domestic market has several manufacturers with the drug registration certificate, including Beijing Four Rings Kebo Pharmaceutical Co., Ltd., Yangtze River Pharmaceutical Group Co., Ltd., and Tianjin Tianshili Zhiqiao Pharmaceutical Co., Ltd. [1] Industry Summary - According to data from Minai Network, the projected domestic market sales for injectable Nicorandil in 2024 are approximately RMB 620 million [1]

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the injection of Nicorandil, which is classified as a Class 3 chemical drug for unstable angina, indicating a significant development in its product portfolio [1] Group 1: Product Approval - The injection of Nicorandil is approved with a specification of 12mg [1] - This drug was first launched in Japan in September 1993 and has not been imported as an original research product in China [1] Group 2: Market Potential - According to Mi Nei Network, the projected domestic market sales for Nicorandil in 2024 are approximately 620 million yuan [1] Group 3: R&D Investment - The company has invested around 6.78 million yuan in the research and development of this product [1] Group 4: Competitive Advantage - The approval of this product is seen as a means to enhance the company's product line and competitiveness, as it is considered to have passed the consistency evaluation [1] Group 5: Market Challenges - The production and sales of the drug may be influenced by various factors, indicating potential challenges in the market [1]

Core Viewpoint - *ST Sailong (002898.SZ) has recently received approval from the National Medical Products Administration for the injection of Nicorandil, which is indicated for the treatment of unstable angina pectoris [1] Company Summary - The wholly-owned subsidiary of *ST Sailong, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has obtained the drug registration certificate for injectable Nicorandil [1]

Group 1 - The core point of the article is that *ST Sailong has received approval from the National Medical Products Administration for its injectable Nicorandil product, which is a significant development for the company [1] - As of January to June 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing sector, 39.78% from the electronics sector, and 0.4% from other businesses [1] - The current market capitalization of *ST Sailong is 2.3 billion yuan [1]

Core Viewpoint - *ST Sailong (002898) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which is used for the treatment of unstable angina pectoris [1] Group 1 - The approval of injectable Nicorandil represents a significant milestone for the company in expanding its product portfolio [1] - Injectable Nicorandil is specifically indicated for the treatment of unstable angina pectoris, addressing a critical medical need in the cardiovascular sector [1]

Core Viewpoint - The company has received approval for the injectable Nicorandil from the National Medical Products Administration, which is intended for the treatment of unstable angina pectoris, enhancing its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently obtained the drug registration certificate for injectable Nicorandil [1] - The approval of injectable Nicorandil will further enrich the company's formulation varieties [1] Group 2: Market Considerations - The sales performance of the newly approved drug will depend on various internal and external environmental changes, indicating a level of uncertainty [1] - The company commits to timely information disclosure based on subsequent developments [1]

Core Insights - Nicorandil tablets, a classic anti-angina drug with over 40 years on the market, have seen a resurgence in interest, with annual sales exceeding 1.4 billion yuan in hospitals, marking it as a new "hot" product in the industry [1][4][15] Regulatory Developments - Shandong New Era Pharmaceutical Co., Ltd. has had its application for the registration of Nicorandil tablets accepted by the CDE, indicating a move towards market entry [1][14] - The drug is classified as a generic under the 4th category of chemical drugs, with the application date noted as August 26, 2025 [2][14] Market Performance - Nicorandil has accumulated sales of over 10.3 billion yuan in China, with a peak sales figure of 1.9 billion yuan in 2022, followed by a decline to 1.464 billion yuan in 2024, representing an 8.53% year-on-year decrease [4][10] - The sales of Nicorandil tablets have shown a steady increase, reaching 789 million yuan in 2023, a 16.81% increase year-on-year, and projected to rise to 875 million yuan in 2024, a 10.95% increase [8] Competitive Landscape - There are currently 60 companies approved to produce Nicorandil tablets in China, with 14 having passed or deemed equivalent in consistency evaluation [11][14] - The original manufacturer, Chugai Pharmaceutical Co., Ltd., holds a 50% market share, making it a significant player in the field [11] Industry Trends - The treatment of coronary heart disease is seeing an increase in incidence and mortality rates, leading to a competitive environment where generic drugs like Nicorandil are becoming increasingly relevant [10] - The recent national procurement policies have created a challenging landscape for generic drugs, with companies needing to act quickly to secure market opportunities [15]

Core Viewpoint - The company has received approval for the injectable Nicorandil, which is primarily used for treating unstable angina, enhancing its product portfolio in the cardiovascular field [1] Group 1 - The company's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Nicorandil from the National Medical Products Administration [1] - The approval is considered equivalent to passing the consistency evaluation, which will enrich the company's cardiovascular product offerings [1] - This development is expected to strengthen the company's overall market competitiveness in related medication fields and bring positive impacts for future growth [1]